Software
Signal processing, compact models and user experiences designed for compatible devices.
COMPANY
Building the cardiometabolic intelligence layer for existing wearables.
NeuTigers is a Princeton-rooted software company connecting Edge-AI, signal science, clinical evidence and partner execution to create more useful health experiences.
Our company thesis ↓OUR COMPANY THESIS
The device already exists. The intelligence can do more.
Consumer wearables collect increasingly rich physiological signals. NeuTigers develops the software and evidence capabilities that can turn those signals into defined cardiometabolic experiences.
Evidence
Research programs that connect wearable signals with reference measurements and outcomes.
Partner deployment
Co-development and integration with organizations that already reach users, studies and health systems.
Supporting detail: Princeton roots
FROM FOUNDATION TO PORTFOLIO
SweetDeep is the first application, not the end of the story.
StarDeep provides reusable technology and evidence capabilities. SweetDeep applies them first to metabolic wellness. Future cardiometabolic and chronic-disease programs advance only with a defined use case, fit-for-purpose evidence and the appropriate regulatory path.
StarDeep™Technology + evidence foundation→SweetDeep™First commercial application in development→Future programsDefined cardiometabolic applications
Supporting detail: Mission and scale
INVESTOR OVERVIEW
Validated assets entering commercial conversion.
NeuTigers is focused on converting its completed OEM proof of concept, working applications and clinical evidence foundation into recurring licensing and deployment revenue.
De-risked foundation
Proprietary Edge-AI, a multinational research portfolio and working wearable applications.
Scalable model
B2B licensing, integration, co-development and sponsored evidence programs, without manufacturing hardware.
Next milestone
First recurring OEM licensing or deployment revenue and a second independent enterprise channel.
No user-growth or revenue projections are presented on the public website. Detailed assumptions are available through qualified investor diligence.
Discuss an investment ↗LEADERSHIP
Technical depth, clinical perspective and operating experience.
The leadership team brings together AI research, enterprise software, life sciences, finance and international execution.
CEO & Founder
Adel Laoui, PhD, MBA
20+ years of experience in drug development in life sciences and entrepreneurship in digital health; previously at Sanofi and BIOVIA (Dassault Systèmes).
LinkedIn profile ↗
Co-Founder
Prof. Niraj Jha
Professor of Electrical and Computer Engineering at Princeton University; IEEE and ACM Fellow; 34,000+ citations in machine learning, smart healthcare and energy-efficient computing.
Princeton faculty profile ↗
Chief Technology Officer
Vishu Ghanakota
18+ years of experience in enterprise software development with a startup exit; previously at huMetrix and Cisco.
LinkedIn profile ↗
Chief Financial Officer
Paul Moorcroft, CPA
Seasoned finance executive skilled in building highly efficient teams, business planning and operations management; previously at Havas Health Network and BluePrint.
LinkedIn profile ↗
EU Managing Director
Gilles Orciere
Experienced in international strategy and cross-border operations between the US and Europe.
LinkedIn profile ↗BOARD OF DIRECTORS
Governance for disciplined growth.
Board Director
Francois Kress
Seasoned MedTech executive and serial entrepreneur, bridging technology, commercialization and investment strategy; previously with LVMH and RegenLife.
LinkedIn profile ↗
Board Director
John Ravalli
Managing Director at Glenmede, advisor to ultra-high-net-worth individuals, foundations and family offices; previously at FTI and Franklin Templeton.
LinkedIn profile ↗PRINCETON · PARIS